Stock Screener App

Frei -

Installieren

20.92

2.80% 0.57

after-market

Handel nachbörslich: 20.94 0.02 +0.10%

Pharvaris Nv (PHVS)

Überblick Nachrichten Preisverlauf Forum Prognose

Pharvaris Nv Aktie (PHVS) Neueste Nachrichten

(PHVS) Long Term Investment Analysis - Stock Traders Daily

Pharvaris Reports 93% HAE Attack Reduction in Trial Data, Plans Phase 3 Study | PHVS Stock News - StockTitan

Pharvaris to Present HAE Treatment Progress at Guggenheim Healthcare Conference | PHVS Stock News - StockTitan

Trend Tracker for (PHVS) - Stock Traders Daily

Axonis Therapeutics Announces $115 Million Series A Financing - Financial Times

Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting - StockTitan

(PHVS) Proactive Strategies - Stock Traders Daily

Pharvaris (PHVS) Shares Cross Above 200 DMA - Nasdaq

PHVSPharvaris N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at ... - The Hastings Tribune

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings - StockTitan

Pharvaris to Host Virtual Investor Event on October 23, 2024 - StockTitan

(PHVS) Investment Report - Stock Traders Daily

Pharvaris (NASDAQ:PHVS) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Pharvaris (NASDAQ:PHVS) Shares Gap DownShould You Sell? - MarketBeat

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at - The Bakersfield Californian

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop - StockTitan

Novo Holdings A S Buys 556,970 Shares of Pharvaris (NASDAQ:PHVS) - MarketBeat

Pharvaris N.V.'s SWOT analysis: promising HAE drug boosts stock outlook - Investing.com India

Pharvaris CBO Resigns, Team Absorbs Duties - TipRanks

(PHVS) Technical Data - Stock Traders Daily

Hereditary Angioedema Therapeutics Global Market Report Explores 2024: Size Forecast and Growth Prospects 2033 - WhaTech

Pharvaris (NASDAQ:PHVS) Shares Gap Down to $21.09 - MarketBeat

EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma - sharewise

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Paradise, NV – Injuries Reported in Vehicle Accident on I-215 W near Las Vegas Blvd Onramp - Local Accident Reports

Las Vegas, NV – Accident on I-215 E near Windmill Ln Results in Injuries - Local Accident Reports

North Las Vegas Man Charged in Fatal Hit-and-Run After Allegedly Fleeing Accident Scene - Hoodline

Paradise, NV – Vehicle Accident at I-215 E and Las Vegas Blvd - Local Accident Reports

Las Vegas, NV – Vehicle Accident at CC215 S and W Sunset Rd Causes Injuries - Local Accident Reports

Highway reopens outside Las Vegas after crash, fire in semi hauling lithium batteries - KRNV

Road closures persist after trucks carrying wood and batteries collide - News3LV

Appeal over identifying invasive hornets in Jersey - BBC.com

Hwy 95 closes in Nye County after crash involving truck carrying lithium batteries - Audacy

1 person transported to hospital after Henderson crash involving bicyclist - Fox 5 Las Vegas

1 hospitalized in Henderson crash involving bicyclistKLAS - KLAS - 8 News Now

Oregon man dies northwest of Las Vegas Valley, state police say - Fox 5 Las Vegas

1 person taken to hospital after crash involving car, bicyclist in Henderson - News3LV

Rep. Steven Horsford releases updated campaign ad after LVPPA concerns - KTNV 13 Action News Las Vegas

Silver Springs man killed in crash on U.S. 50A & 6th Street in Fernley - KTVN

Las Vegas, NV – Collision at CC215 S & W Flamingo Rd Results in Injuries - Local Accident Reports

Pharvaris (NASDAQ:PHVS) Shares Gap Up After Analyst Upgrade - MarketBeat

Pharvaris stock outlook strengthened with price target increase, Outperform rating reiterated by Oppenheimer - Investing.com UK

(PHVS) Technical Pivots with Risk Controls - Stock Traders Daily

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and ... - The Bakersfield Californian

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant - StockTitan

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024 - StockTitan

Pharvaris Presents Data at the Bradykinin Symposium 2024 - StockTitan

Pharvaris to Present at SVB Securities Global Biopharma Conference - Yahoo Finance UK

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium - Yahoo Finance UK

Pharvaris (NASDAQ:PHVS) Shares Gap Down to $19.08 - MarketBeat

Pharvaris (NASDAQ:PHVS) Stock Price Up 5.2% - MarketBeat

Pharvaris (NASDAQ:PHVS) Trading Down 2.4% - MarketBeat

(PHVS) Trading Advice - Stock Traders Daily

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan

Pharvaris (NASDAQ:PHVS) Shares Up 5.1% - MarketBeat

Price T Rowe Associates Inc. MD Sells 84,783 Shares of Pharvaris (NASDAQ:PHVS) - Defense World

(PHVS) Investment Analysis and Advice - Stock Traders Daily

Viridian, Pharvaris said to be among prime M&A targets for Biogen - Seeking Alpha

Contrasting Avidity Biosciences (NASDAQ:RNA) and Pharvaris (NASDAQ:PHVS) - American Banking and Market News

Pharvaris (NASDAQ:PHVS) Price Target Raised to $38.00 at Oppenheimer - Defense World

SMMT

$18.98

3.66%

INCY

$76.97

1.45%

MRNA

$39.51

7.22%

UTHR

$359.21

1.11%

BGNE

$187.69

0.81%

BNTX

$101.87

2.16%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters